Bactiguard (BACTI) Investor Presentation summary

Global healthcare trends and market opportunity

• Antimicrobial resistance is a major global health threat, linked to nearly 5 million deaths in 2019.

• 1 in 10 patients worldwide are affected by healthcare-associated infections.

• Aging populations and lifestyle diseases are increasing demand for safer, more efficient healthcare.

• The addressable market across orthopedics, urology, intravascular, dental, and wound management is estimated at $80 billion.

Technology and clinical validation

• Over 100,000 patients have participated in clinical trials, with more than 40 studies conducted.

• Recent randomized controlled trials show a 70% reduction in infection risk.

• The technology uses an ultra-thin noble metal coating (gold, silver, palladium) to reduce microbial adhesion and biofilm formation.

• Coated surfaces show significantly fewer bacteria attachment over time compared to uncoated surfaces.

Company background and strategic shift

• Founded in 2005, the technology is based on a concept nearly a century old, refined in the 1970s.

• Over 230 million coated Foley catheters have been sold in the US with no reported adverse events related to the coating.

• In 2023, the company made its largest strategic shift, focusing on licensing.

• The new mission is to become the global standard for preventing device-related infections through partnerships.